Related Experiment Video
Updated: Jul 13, 2026
10:44
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Proteasome inhibition and multiple myeloma
Pamela Kanagasabaphy1, Gareth J Morgan, Faith E Davies
1Royal Marsden Hospital, Haemato-Oncology Unit, Downs Road, Sutton, Surrey SM2 5PT, UK.
Current Opinion in Investigational Drugs (London, England : 2000)
|July 12, 2007
Summary
Novel proteasome inhibitors, like bortezomib, offer a breakthrough in multiple myeloma treatment. This approach targets cancer cell death, improving survival rates for patients resistant to other therapies.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Understanding multiple myeloma biology drives the search for targeted therapies.
- Proteasome inhibition is a key strategy in myeloma treatment.
- Bortezomib, a novel proteasome inhibitor, represents a significant advancement.
Purpose of the Study:
- To review the biology of the proteasome and its role in myeloma.
- To explain the mechanism of proteasome inhibition-induced myeloma cell death.
- To discuss the clinical application of proteasome inhibitors in myeloma management.
Main Methods:
- Literature review of proteasome biology.
- Analysis of bortezomib's mechanism of action.
- Discussion of clinical trial data and outcomes.
Main Results:
- Proteasome inhibition effectively induces myeloma cell death.
- Bortezomib demonstrates efficacy in refractory myeloma patients.
- Increased progression-free and overall survival rates are observed with bortezomib treatment.
Conclusions:
- Proteasome inhibitors are a vital therapeutic class for multiple myeloma.
- Bortezomib has established itself as a cornerstone treatment.
- Further research into proteasome inhibition continues to refine myeloma therapy.
Related Concept Videos
01:13The Proteasome
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
02:18The Proteasome
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
02:18The Proteasome
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:25Inhibitors of Bacterial Protein Synthesis
Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...